Comparative Pharmacology
Head-to-head clinical analysis: DIUTENSEN R versus METATENSIN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUTENSEN R versus METATENSIN 4.
DIUTENSEN-R vs METATENSIN #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing cGMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
None Documented
None Documented
Terminal half-life: cryptenamine 9-10 h, methylothiazide 18-24 h, reserpine 50-100 h (prolonged due to enterohepatic recirculation and tissue binding; accumulation occurs with daily dosing)
12-18 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 59% (cryptenamine), 50% (methylothiazide), 7% (reserpine); Biliary/fecal: 21% (cryptenamine), 48% (methylothiazide), 90% (reserpine)
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination